ArticleThoracic cancer2021

Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.

Hisao Imai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.